- Home
- CLEU vs SLXN Comparison
CLEU vs SLXN Comparison
Compare CLEU & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- SLXN
- Stock Information
- Founded
- CLEU 2011
- SLXN 2008
- Country
- CLEU China
- SLXN Israel
- Employees
- CLEU N/A
- SLXN N/A
- Industry
- CLEU Other Consumer Services
- SLXN
- Sector
- CLEU Real Estate
- SLXN
- Exchange
- CLEU Nasdaq
- SLXN NYSE
- Market Cap
- CLEU 1.0B
- SLXN 5.2M
- IPO Year
- CLEU 2020
- SLXN N/A
- Fundamental
- Price
- CLEU $3.88
- SLXN $2.15
- Analyst Decision
- CLEU
- SLXN Strong Buy
- Analyst Count
- CLEU 0
- SLXN 1
- Target Price
- CLEU N/A
- SLXN $9.00
- AVG Volume (30 Days)
- CLEU 277.9K
- SLXN 1.0M
- Earning Date
- CLEU 01-14-2025
- SLXN 02-21-2025
- Dividend Yield
- CLEU N/A
- SLXN N/A
- EPS Growth
- CLEU N/A
- SLXN N/A
- EPS
- CLEU N/A
- SLXN N/A
- Revenue
- CLEU $2,413,409.00
- SLXN N/A
- Revenue This Year
- CLEU N/A
- SLXN N/A
- Revenue Next Year
- CLEU N/A
- SLXN N/A
- P/E Ratio
- CLEU N/A
- SLXN N/A
- Revenue Growth
- CLEU N/A
- SLXN N/A
- 52 Week Low
- CLEU $0.12
- SLXN $0.21
- 52 Week High
- CLEU $5.00
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CLEU 75.94
- SLXN N/A
- Support Level
- CLEU $0.12
- SLXN N/A
- Resistance Level
- CLEU $5.00
- SLXN N/A
- Average True Range (ATR)
- CLEU 0.51
- SLXN 0.00
- MACD
- CLEU 0.37
- SLXN 0.00
- Stochastic Oscillator
- CLEU 77.04
- SLXN 0.00
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.